
Researchers have examined whether high-dose influenza vaccination might influence the risk of Alzheimer’s disease, comparing outcomes for people who received the larger-dose formulation with those who got the standard version.
Study design and key findings
The analysis drew on a national claims database that recorded about 120,000 recipients of the high-dose vaccine and roughly 44,000 who received the standard dose. Investigators matched the two groups on a range of observable characteristics and followed them for about three years.
During that period, the high-dose group experienced a modestly lower incidence of diagnosed Alzheimer’s disease and other dementias. The authors calculated that between 185 and 270 people would need to be vaccinated with the high-dose product to prevent a single case of Alzheimer’s, indicating a small absolute effect.
Safety signals were limited. Fever occurred somewhat more often after the high-dose injection, but serious adverse events did not rise compared with the standard formulation.
One striking observation was an apparent reduction in dementia diagnoses within the first month after vaccination. Because Alzheimer’s disease typically develops over many years, the rapid timing of this association has puzzled experts.
Limitations and interpretation
The study’s observational nature means causality cannot be established. Claims data were used to identify dementia cases, and such records can miss diagnoses or misclassify conditions.
Researchers also noted the possibility of “healthy vaccinee bias”: individuals who obtain vaccinations may also engage in other health-promoting behaviors that lower dementia risk, such as regular exercise or a balanced diet.
Read Also: XDR Shigella Spreads Beyond High-Risk Groups in LA County
Gender-specific patterns emerged, with women showing an earlier association and men a later one. Biological differences in immune response could underlie these findings, but the data do not provide a definitive explanation.
Because the database lacked laboratory results, imaging, or direct cognitive testing, the analysis could not incorporate biomarkers that might clarify disease status. Death records were unavailable, preventing assessment of competing mortality risks.
Only about five percent of the cohort was older than 65, limiting insight into the age group most vulnerable to Alzheimer’s disease. The relatively short follow-up also constrains interpretation of long-term effects.
While the observed link is intriguing, it should not change clinical practice at this stage. Influenza vaccination remains essential for preventing flu-related complications, and the high-dose product is already recommended for older adults because it offers stronger protection against infection.
A senior medical director at a memory center in Illinois noted that the current study aligns with broader research on vaccines and dementia risk, including investigations into herpes zoster, Tdap, and BCG immunizations. The herpes zoster vaccine, in particular, has shown the strongest evidence of an association with reduced dementia risk, though no vaccine has yet proven to directly prevent or eliminate the disease. The newer recombinant zoster vaccine, Shingrix, and respiratory syncytial virus (RSV) vaccines—both of which use adjuvants—have also generated interest in their potential links to cognitive health.
Comparisons with other vaccine studies
While the influenza findings are preliminary, they build on prior observational work suggesting that certain vaccines may influence dementia risk through mechanisms beyond their primary protective effects. For example, the herpes zoster vaccine has been studied more extensively in this context, with multiple analyses indicating a possible reduction in dementia diagnoses among recipients. Unlike influenza, which targets a respiratory infection, the zoster vaccine may exert effects through immune modulation that extends beyond infection prevention, though the exact pathways remain unclear.
Methodological challenges and future directions
The study’s reliance on claims data introduced several limitations, including the absence of direct clinical assessments or biomarkers. Diagnoses of Alzheimer’s and other dementias were identified through administrative records, which can underrepresent cases or misclassify conditions. For instance, mild cognitive impairment (MCI) was sometimes associated with a higher risk of dementia in certain analyses, depending on how it was defined, a counterintuitive result that highlights the fragility of claims-based diagnoses. The lack of laboratory results, imaging, or cognitive testing also prevented the study from incorporating biomarkers like amyloid or tau levels, which could clarify whether observed associations reflect true disease modification or other factors.